Multiparametric MRI-based radiomics nomogram for differentiation of primary mucinous ovarian cancer from metastatic ovarian cancer
Abdominal Radiology · 2024
DOI: 10.1007/s00261-024-04542-y ↗Kurz gefasst
Fachartikel in der Zeitschrift Abdominal Radiology, 2024. Verfasst von Shu Yi Shi und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Jinshan Hospital, Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Nomograms, Ovarian Neoplasms, Multiparametric Magnetic Resonance Imaging, Adenocarcinoma, Mucinous. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: Jinshan District Health System, Shanghai Municipal Health System.
Abstract (Originalsprache)
OBJECTIVE: To develop a multiparametric magnetic resonance imaging (mpMRI)-based radiomics nomogram and evaluate its performance in differentiating primary mucinous ovarian cancer (PMOC) from metastatic ovarian cancer (MOC). METHODS: A total of 194 patients with PMOC (n = 72) and MOC (n = 122) confirmed by histology were randomly divided into the primary cohort (n = 137) and validation cohort (n = 57). Radiomics features were extracted from axial fat-saturated T2-weighted imaging (FS-T2WI), diffusion-weighted imaging (DWI), and contrast-enhanced T1-weighted imaging (CE-T1WI) sequences of each lesion. The effective features were selected by minimum redundancy maximum relevance (mRMR) and least absolute shrinkage and selection operator (LASSO) regression to develop a radiomics model. Combined with clinical features, multivariate logistic regression analysis was employed to develop a radiomics nomogram. The efficiency of nomogram was evaluated using the receiver operating characteristic (ROC) curve analysis and compared using DeLong test. Finally, the goodness of fit and clinical benefit of nomogram were assessed by calibration curves and decision curve analysis, respectively. RESULTS: The radiomics nomogram, by combining the mpMRI radiomics features with clinical features, yielded area under the curve (AUC) values of 0.931 and 0.934 in the primary and validation cohorts, respectively. The predictive performance of the radiomics nomogram was significantly superior to the radiomics model (0.931 vs. 0.870, P = 0.004; 0.934 vs. 0.844, P = 0.032), the clinical model (0.931 vs. 0.858, P = 0.005; 0.934 vs. 0.847, P = 0.030), and radiologists (all P < 0.05) in the primary and validation cohorts, respectively. The decision curve analysis revealed that the nomogram could provide higher net benefit to patients. CONCLUSION: The mpMRI-based radiomics nomogram exhibited notable predictive performance in differentiating PMOC from MOC, emerging as a non-invasive preoperative imaging approach.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiology, Jinshan Hospital, Fudan University, Shanghai, China.
- Department of Radiology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
- Department of Radiology, Changzhi People's Hospital, Changzhi, Shanxi, China.
- Department of Radiology, Jinshan Hospital, Fudan University, Shanghai, China. dr.jinweiqiang@163.com.
Förderung
- Jinshan District Health System
- Shanghai Municipal Health System
Zitieren
APA
Shi, S. Y., Li, Y. A., & Qiang, J. W. (2024). Multiparametric MRI-based radiomics nomogram for differentiation of primary mucinous ovarian cancer from metastatic ovarian cancer. Abdominal Radiology. https://doi.org/10.1007/s00261-024-04542-y
Vancouver
Shi SY, Li YA, Qiang JW. Multiparametric MRI-based radiomics nomogram for differentiation of primary mucinous ovarian cancer from metastatic ovarian cancer. Abdominal Radiology. 2024. doi:10.1007/s00261-024-04542-y
BibTeX
@article{Shi2024,
author = {Shi, Shu Yi and Li, Yong Ai and Qiang, Jin Wei},
title = {Multiparametric MRI-based radiomics nomogram for differentiation of primary mucinous ovarian cancer from metastatic ovarian cancer},
journal = {Abdominal Radiology},
year = {2024},
doi = {10.1007/s00261-024-04542-y}
}
EUVIMED